**Core Concept**
The question is testing the knowledge of radioisotopes used in permanent implants for brachytherapy, a type of internal radiation therapy. Brachytherapy involves placing radioactive material directly into or near the tumor site to deliver high doses of radiation with minimal damage to surrounding healthy tissues.

**Why the Correct Answer is Right**
Permanent implants are typically used for low- to intermediate-risk prostate cancer, and the most commonly used radioisotopes for this purpose are Iodine-125 ((^{125})I) and Palladium-103 ((^{103})Pd). These isotopes have relatively long half-lives, allowing them to deliver radiation over an extended period without the need for surgical removal. In contrast, Iridium-192 ((^{192})Ir) is commonly used in temporary implants, such as in the treatment of cervical and endometrial cancers, due to its shorter half-life and the need for surgical removal after treatment.

**Why Each Wrong Option is Incorrect**
**Option A:** Iodine-125 ((^{125})I) is a commonly used radioisotope for permanent implants in prostate cancer.
**Option C:** Palladium-103 ((^{103})Pd) is another commonly used radioisotope for permanent implants in prostate cancer.

**Clinical Pearl / High-Yield Fact**
When considering brachytherapy for prostate cancer, it's essential to weigh the benefits of permanent implants against the potential risks of seed migration or radiation exposure to surrounding tissues. A thorough discussion with the patient about the risks and benefits of each treatment option is crucial.

**Correct Answer: D. Iridium-192 ((^{192})Ir) is not used as a permanent implant.**